Clinical Oncology and Cancer Research最新文献

{"title":"Advanced research on neoadjuvant therapy with trastuzumab in HER2-positive breast cancer","authors":"Jun Liu, Yanfang Yang, L. Gu","doi":"10.3969/J.ISSN.1000-8179.20132207","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20132207","url":null,"abstract":"Trastuzumab is a specific inhibitor against human epidermal growth factor receptor-2 (HER-2). Trastuzumab is widely used in the neo-adjuvant treatment of HER-2 breast cancer. Large-scale randomized and controlled clinical trials have demonstrated that pathologic complete response rates (pCRs) were significantly increased with neo-adjuvant trastuzumab therapy plus chemotherapy than with regular chemotherapy. The use of trastuzumab plus chemotherapy with lapatinib supplements could further improve pCR rates. Anthracycline and non-anthracycline drugs could both be used concurrently with trastuzumab. Endocrine therapy could be used as an alternative for estrogen receptor-positive patients. pCR is a powerful predictor of long-term outcomes in HER-2 positive patients under neo-adjuvant therapy with trastuzumab. However, patient loss of HER-2 expression with residual disease after neo-adjuvant therapy with trastuzumab is a poor prognostic factor. This study paper will provide a review of related research.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129948031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of clinical characteristics of 310 patients with moderate to severe cancer pain","authors":"Y. Shao, Kun Wang","doi":"10.3969/J.ISSN.1000-8179.20140431","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140431","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114282967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroblastoma in adults: Diagnosis and treatment","authors":"Yanna Cao, Jie Yan, Huijuan Wang","doi":"10.3969/J.ISSN.1000-8179.20140586","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140586","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115504521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of SHP2 in invasion and metastasis of breast cancer","authors":"Qinanqian Chen, Ying Zheng, Bin Zhang, Xuchen Cao","doi":"10.3969/J.ISSN.1000-8179.20131850","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131850","url":null,"abstract":"Src homology 2 domain-containing phosphatase (SHP2), which is encoded by proto-oncogene PTPN11, is one of the transmembrane protein-tyrosine phosphatases. SHP2 has an important function in signal transduction pathways and activities of cells through the regulation of tyrosine phosphorylation level of intracellular proteins. The status of SHP2 activation is closely connected with the regulation of hormone levels, state of invasion and metastasis of tumor, development and progression of tumor stem cells of breast cancer, as well as signal pathways including Ras/ERK and PI3K/Akt/mTOR. Gene knockout or gene silencing expression helps inhibit tumor growth, irreversibly hindering the ability of the tumor to regain stem cells and disturb the signal pathways of the invasion and metastasis of breast cancer. Recent studies have shown that SHP2 may help in bringing anticancer drugs to a higher level. This article concentrates on the research progress in relationship of SHP2 with invasion and metastasis of breast cancer.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115883595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between activated circulating endothelial cells and efficacy of anti-angiogenic therapy in non-small cell lung cancer patients","authors":"Xi-yin Wei, Jing Wang, F. Zang, Fei Zhang, Zhu-jun Liu, Cui-cui Zhang, Kai Li","doi":"10.3969/J.ISSN.1000-8179.20140973","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140973","url":null,"abstract":"Objective: This study aimed to examine the number of activated circulating endothelial cells (aCECs) in the peripheral blood of patients with non-small cell lung cancer (NSCLC), and investigate the relationship among aCECs, anti-angiogenic therapy, and prognosis of NSCLC patients. This study also aimed to identify novel predictive markers for anti-angiogenic therapy, and provide basic data and experimental basis for establishing an evaluation system for this therapy. Methods: A total of 142 NSCLC patients were randomly divided into the chemotherapy group (Group 1) and combined therapy group (i.e., chemotherapy plus endostatin, Group 2). The number of aCECs was measured using flow cytometry by detecting the expression status of CD105 and CD146 in the peripheral blood. The correlation between the changes in aCECs and efficacy of drug treatment was statistically analyzed using SPSS software. Results: The number of aCECs in Group 2 increased significantly at 8 and 29 d, two cycles, 50 and 71 d, and four cycles after treatment, respectively (P<0.05). In particular, aCECs amount in cases of progressive disease increased more significantly after combined therapy (P<0.05). A negative correlation was found between the treatment cycle and difference in aCECs amount before and after therapy (r= -0.970, P=0.001). A negative correlation was also observed between the difference in aCECs amount and time to tumor progression (TTP) (r=-0.351, P=0.039). Therefore, the difference in aCECs amount before and after therapy could serve as an important predictor for TTP in NSCLC patients. Conclusion: CD105 and CD146 reflected the activation status of endothelial cells, and responded to the drug treatment. Thus, CD105 and CD146 could act as ideal markers for aCECs. The number of aCECs increased during cancer progression, but significantly decreased after long-term treatment. Therefore, the change in aCECs amount may be a useful marker in predicting the efficacy of anti-angiogenic therapy.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114901649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress in notch signaling pathway in breast cancer stem cells","authors":"R. Guo, Jin Zhang","doi":"10.3969/J.ISSN.1000-8179.20140812","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140812","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122795278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of radiotherapy for newly diagnosed multiple myeloma with extramedullary disease","authors":"T. Yuan, Shanqi Guo, Ya-qin Zhi, Qian Li, B. Xia, Yafei Wang, Yizhuo Zhang, Ping Wang","doi":"10.3969/J.ISSN.1000-8179.20140931","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140931","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126001798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BAG-1, EGFR, and PARP-1 expressions in breast cancer and their clinical significance","authors":"Rongrong Wang, Xiao Liu, Su Lu, L. Gu, R. Xiang, Hong Liu","doi":"10.3969/J.ISSN.1000-8179.20140116","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140116","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"145 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133309089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of multiple myeloma treatment strategies based on changes in effect judgment","authors":"Yizhuo Zhang, Yafei Wang","doi":"10.3969/J.ISSN.1000-8179.20140928","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140928","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129562597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation and clinical significance of P53 expression with epithelial-mesenchymal transition in breast cancer","authors":"L. Huo, Hui Li, F. Wei, X. Ren","doi":"10.3969/J.ISSN.1000-8179.20140603","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140603","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116802947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}